Dr Cheriyan has been a Consultant Physician and Clinical Pharmacologist at Addenbrooke’s Hospital, Cambridge, UK since 2006, and is an Affiliated Assistant Professor in the Department of Medicine, University of Cambridge. He trained initially in Sheffield, and subsequently in Nottingham and London before completing his specialist training Cambridge.
He is an active clinical researcher with interests in cardiovascular medicine particularly vascular function and inflammation. He is one of a few clinical triallists working on early phase experimental medicine studies of novel therapeutics, and has a unique post which combines close collaboration with industrial partners on the Addenbrooke’s Biomedical Campus. His clinical service commitments are to the Department of Acute Medicine at Addenbrooke’s Hospital. He is the Vice Chair of the local Research Ethics Committee, a member of the Management Board of the Cambridge Clinical Trials Unit and until 2020 served as a Senior Physician and Clinical Pharmacologist seconded to the GSK CUC in Cambridge. He has co-authored the Oxford Specialist Handbook on Hypertension and is also co-founder of the Cambridge Medical Seminars. Apart from work, he is a keen traveller and connoisseur of fine dining!
Dr. Ben Challis completed his undergraduate training in Biochemistry & Chemistry at the University of Western Ontario.
He obtained his PhD at the University of Cambridge, where he also obtained his MB BChir and completed specialist medical training in Internal Medicine & Endocrinology and Diabetes as a NIHR funded Academic Clinical Lecturer.
His research has focused on the genetics of metabolic disease, particularly obesity and disorders of glucose metabolism, and more recently, endocrine oncology. He is currently an Honorary Consultant in Endocrinology at Addenbrooke’s Hospital in Cambridge.
In September 2016, Ben joined AstraZeneca as Associate Director Physician in the Clinical Discovery Unit of Early Clinical Development where his work includes development of genetic- and biomarker-based strategies for human target validation, drug repurposing and experimental medicine studies.
Dr Ambery has considerable experience across all phases of clinical development in cardiovascular and metabolic diseases (CVMD) in the pharmaceutical industry.
Having worked in medical affairs, early and latedevelopment for GSK from 2001-2014, he joined Medimmune where he is the lead member for the CVMD clinical group in Cambridge.
He has a particular interest in incretins for the treatment of Type 2 diabetes and in Type 1 diabetes immune modulation.
He is a specialist partner for the General Medical Council in academic or research certification, taking a particular interest in the licensing of doctors via the academic route, and still practises as an Acute Medicine Physician in Addenbrookes.
Focuses on understanding the biological pathways underlying systemic hypertension and arteriosclerosis, with a strong emphasis on basic physiology, experimental/translational medicine and early phase interventional clinical trials. My group has expertise in vascular physiology/pharmacology, hypertension, endothelial biology and trial design.
email@example.com Tel: 01223 761495